Mindprint implements market-leading automation solution for Ockham Oncology

Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.

Mindprint, a Toronto-based company specializing in software management solutions for the Contract Research industry, has worked onsite with Ockham to customize the new management tool, which went live in December 2013.

"Our passion is helping companies fight cancer," said Jim Baker, CEO of Ockham, which includes a global division solely focused on cancer drug trials. "We have successfully completed more than 250 oncology trials for some of the leading pharma companies.

"Because of the operational complexity in managing global trials, our conventional software tools have become cumbersome. After extensive research, we chose Mindprint as our solution."

Ockham continues to experience fast growth just two years after the successful integration of Nexus Oncology a Scotland-based oncology CRO. Mindprint, which specializes in CRO software solutions, prepared an operational plan while working closely with the Ockham team.

"We interviewed the key subject matter experts for Ockham Oncology," said Prasad A. Sristi, CEO of Mindprint."We were able to use our library of CRO solutions for demo purposes to gather quality feedback and build consensus about what Ockham needed." Both Sristi and Baker praised the thorough review of Ockham's business.

"These new tools help us serve our clients more effectively and preserve our essential focus on the clinical challenge in helping our clients in developing new cancer-fighting formulations," Baker said.

Mindprint implemented a professional services automation (PSA) tool customized for Ockham's needs. A key part of the PSA allows Ockham to measure the profitability of each clinical study - a challenging aspect of every trial due to the many data sources associated with each trial.

Sristi said the core of the technology is the patented Axpert platform developed in Bangalore by India-based Agile Labs. This tool allow the customization of enterprise management systems without extensive hard coding.

Baker praised Mindprint software's capacity to do much more for their business in addition to generating interactive reports on profitability. "The system implemented by Mindprint is exactly what we needed," Baker said. "When we began implementation, we realized that if utilized correctly Mindprint can be fundamental to our business and meet our growth demands."

The new software tools allow "much more accurate financial data and financial forecasts for our entire company," Baker said.

About Ockham
Launched in 1986, Ockham is a global oncology CRO and full-spectrum global resourcing company. Clinical expertise, therapeutic focus, and successful oncology trial outcomes have created an industry leadership position for Ockham Oncology. Ockham Source continues to achieve sustained success by offering traditional sourcing solutions as well as a growing FSP (Functional Service Provider). Ockham’s world headquarters is based in Cary, North Carolina, with the European headquarters located in Roslin, Scotland, near Edinburgh. Ockham offices are located strategically around the world to serve global customers.

About Mindprint
Mindprint Inc. specializes in serving Contract Research Organizations and pharmaceutical companies with cloud-based enterprise software solutions that provide direct business benefits such as enhanced profitability, streamlined business processes and superior customer value. Launched in 2009 and headquartered in Markham, Ontario, Mindprint has partnered with a number of leading CROs and understands the life cycle of a clinical study as well as the business challenges and system requirements unique to the life sciences industry. Mindprint's library of CRO modules, based on the Axpert enterprise resource planning platform enables rapid custom software development without expensive coding. Read more about Mindprint Inc.

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...